Layal Al Mahmasani MD , James J. Harding MD , Ghassan Abou-Alfa MD, MBA
{"title":"Immunotherapy","authors":"Layal Al Mahmasani MD , James J. Harding MD , Ghassan Abou-Alfa MD, MBA","doi":"10.1016/j.hoc.2024.01.005","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":55060,"journal":{"name":"Hematology-Oncology Clinics of North America","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology-Oncology Clinics of North America","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0889858824000054","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
胆道癌症的发病率持续上升，死亡率也很高。大多数患者都是晚期患者。针对 IDH、FGFR、HER2、BRAFV600 E 等可靶向基因组改变的发现，促进了胆道癌新型疗法的确定和验证。最近的进展表明，在化疗中加入免疫检查点抑制剂可改善疗效，从而确立了新的一线治疗标准。如果存在使用检查点抑制剂的禁忌症和缺乏靶向性改变，化疗仍然是标准的治疗方法。
期刊介绍：
Hematology/Oncology Clinics updates you on the latest trends in patient management, keeps you up to date on the newest advances, and provides a sound basis for choosing treatment options. Under the direction of an experienced guest editor, each issue focuses on a single topic in hematology and oncology, including hemostasis and thrombosis, molecular and cellular basis of hematology, coagulation disorders, and cancers—bone, gastrointestinal, head and neck, lymphomas, neuroendocrine, breast, renal cell, melanoma, and more.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
